Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Summary
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab Combined With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Resectable Rectal Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
165
Start Date
2026-03
Completion Date
2035-11
Last Updated
2026-03-06
Healthy Volunteers
No
Interventions
Adebrelimab in combination with SHR-8068 and chemotherapy
Adebrelimab in combination with SHR-8068 and chemotherapy
Adebrelimab combined with chemotherapy
Adebrelimab combined with chemotherapy
chemotherapy
chemotherapy
Locations (1)
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China